EDGAR·FLOW

Most material SEC filings — November 9, 2026

50 filings analyzed. Top movers: Childrens Place, Inc., CKX LANDS, INC., InMed Pharmaceuticals Inc., HERON THERAPEUTICS, INC. /DE/, Marygold Companies, Inc..
8-K Childrens Place, Inc.
The Children's Place, Inc. (market cap ~$38M) voluntarily filed for Chapter 11 bankruptcy on November 8, 2026, in the District of New Jersey. The company is pursuing a court-supervised Section 363 asset sale with bid deadline of December 9, 2026, targeting completion by end of December 2026. All stores and e-commerce remain open; the company will fund operations and the sale process via a new term loan from existing secured lenders and has engaged GA Group, Tiger Group, and SB360 Capital Partners for inventory liquidation consulting.
▼ Likely negative · significance 96 · 8-K Agent
8-K CKX LANDS, INC.
Jacobs Private Equity II, LLC (JPE) and co-investors (led by HRTG Partners) will invest $1 billion cash in CKX Lands: $900M from JPE and $100M from co-investors. Upon closing, JPE will own ~99.78% on a fully diluted basis; Brad Jacobs becomes Chairman/CEO while keeping QXO role. CKX will declare $20.8M dividend ($10.13/share), undergo 4.1744380:1 reverse split, convert to Delaware corp, and rename to pursue acquisitions in an undetermined industry. Closing expected early 2027, subject to stockholder approval (28% have already committed voting support).
▲ Likely positive · significance 92 · 8-K Agent
8-K InMed Pharmaceuticals Inc.
InMed Pharmaceuticals completed a merger with Mentari Therapeutics on November 9, 2026. The combined entity raised $490 million gross in private placements led by Fairmount (including $50 million convertible note conversion), with participation from 17+ investment firms. Post-merger, ~58.3 million shares outstanding; company trades on Nasdaq under ticker MTRI with cash runway into 2029 to fund migraine drug pipeline (MT-001 Phase 1 data mid-2027; MT-002 regulatory filing Q1 2027, data end-2027).
▲ Likely positive · significance 92 · 8-K Agent
8-K HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics announced Q3 2026 net revenue of $35.3M (down 7.8% from $38.2M in Q3 2025), with ZYNRELEF up 13.8% and APONVIE up 49.3% YoY, but CINVANTI down 16.6%. More significantly, the company entered into a definitive asset purchase agreement whereby CorMedix Therapeutics will acquire substantially all of Heron's assets, subject to stockholder approval and customary closing conditions. Heron ended Q3 with $23.4M in cash and equivalents, and commercial sales of SUSTOL ceased September 30, 2026.
▼ Likely negative · significance 92 · 8-K Agent
8-K Marygold Companies, Inc.
Marygold announced a definitive merger agreement with Madison Dearborn Partners funds to acquire all outstanding shares at $2.00 per share, a 100% premium over the September 24, 2026 closing price. The transaction is expected to close in H1 2027 subject to customary closing conditions. Concurrently, Q1 FY2027 results showed revenue of $9.4M (continuing operations) versus $5.2M YoY, net income of $1.8M ($0.04/share) versus loss of $0.4M ($0.01/share) YoY, driven primarily by USCF Investments' revenue nearly doubling to $8.4M on assets under management reaching $5.5B.
▲ Likely positive · significance 92 · 8-K Agent
8-K Microvast Holdings, Inc.
Microvast reported Q3 2026 revenues of $45.8M (down 62.8% YoY from $123.3M), driven by 62.2% volume decline across Europe and APAC due to softer heavy-duty truck demand. Gross margin collapsed to 5.2% from 37.6%, primarily from a $9.3M write-down of obsolete ESS inventory components. The company recorded a $76.8M net loss (vs. $1.5M loss in Q3 2025), including $35.7M in long-lived asset impairments across China ($15M), Germany ($4.4M), and U.S. ($16.3M). Cash fell to $124.4M (from $169.2M at year-end 2025), with $177M total debt due, including $41.7M convertible bonds due January 31, 2027, and $84M short-term bank loans. Management disclosed substantial doubt about going concern; refinancing discussions are ongoing but uncertain.
▼ Likely negative · significance 92 · 8-K Agent
8-K Edesa Biotech, Inc.
Edesa Biotech granted exclusive rights to paridiprubart in Japan to KYORIN Pharmaceutical for ARDS treatment. Edesa receives $12M upfront plus up to $134M in development/regulatory/sales milestones and double-digit tiered royalties on net sales. Edesa retains all rights outside Japan; Kyorin gains right of first negotiation for AKI and non-exclusive negotiation rights for other indications.
▲ Likely positive · significance 88 · 8-K Agent
8-K Future Vision II Acquisition Corp.
On 2026-11-05, Future Vision II Acquisition Corp. (public market value ~$61.4M) filed an 8-K reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific dollar amounts, counterparty names, or detailed circumstances—only that a delisting notice or listing rule failure occurred and a transfer of listing is involved. The actual facts and timeline of the delisting event are not disclosed in the materials provided.
▼ Likely negative · significance 88 · 8-K Agent
8-K ULTRALIFE CORP
On October 27, 2026, EnerSys (NYSE: ENS) agreed to acquire Ultralife in an all-cash transaction valued at approximately $320 million including net debt assumption, expected to close Q1 2027. Q3 2026 showed revenue of $48.3M (+11.3% YoY), gross profit of $13.3M (27.5% margin vs 22.2%), operating income of $3.2M vs loss of $1.0M prior year, and EPS of $0.14 vs ($0.07). Backlog reached record $136.0M, driven by 56.7% growth in government/defense sales.
▲ Likely positive · significance 88 · 8-K Agent
8-K Surgery Partners, Inc.
Surgery Partners amended its HealthSpan Partners merger agreement on November 9, 2026, increasing consideration from an undisclosed prior price to $25.00 per share in cash, implying ~$6.0 billion enterprise value. Stockholders (excluding Bain Capital affiliates) receive 10% per annum ticking fee if closing delays past March 1, 2027. Q3 2026 revenue declined 0.8% YoY to $815.3M; same-facility revenue grew 6.0%; Adjusted EBITDA was $132.7M. Merger expected to close Q1 2027 pending stockholder approval and regulatory clearance.
▲ Likely positive · significance 88 · 8-K Agent
8-K Reliance Global Group, Inc.
Reliance Global Group (market cap ~$5.3M) completed an all-cash acquisition of Oblivus, a GPU cloud computing platform and marketplace, from Skyportal Inc. on November 3, 2026. Purchase price: $3.0M upfront + up to $750K in milestone payments ($375K in escrow at closing) if business achieves $79K average monthly revenue in first 6 months and $120K in second 6 months. Founder Matthew Antoun receives $250K consulting fees over 12 months plus up to $600K in contingent stock grants. Oblivus generated ~$1.5M annual revenue; Reliance remains debt-free.
▲ Likely positive · significance 87 · 8-K Agent
8-K SHF Holdings, Inc.
On October 23, 2026, SHF Holdings (market cap ~$3.1M) entered a nonbinding term sheet with Opifex Media Inc. to merge; Opifex holders would own ~85% of the combined company post-close, SHF shareholders ~15% (adjustable 12.5–17.5%). Separately, a reverse stock split trigger on September 30, 2026 reset Series B conversion price from $18.6336 to $0.1210 per share; from October 22–November 6, Series B holders converted 19,529 shares into 131.2M common shares, diluting common count from 1M to 132M. Company faces Nasdaq delisting risk (stock at $0.10 or below for 8 consecutive days; delisting auto-triggers if 10 consecutive days occur), has limited liquidity ($4.4M cash vs. $2.95M quarterly burn), going-concern doubt, and pending Abaca litigation (potential loss $0–$7.8M).
▼ Likely negative · significance 82 · 8-K Agent
10-Q Babcock & Wilcox Enterprises, Inc.
Babcock & Wilcox Enterprises obtained its eleventh amendment to its credit agreement (dated August 11, 2026) with Axos Bank as administrative agent. The amendment permits share repurchases up to $50,000,000 by August 11, 2027, under a program announced July 13, 2026, without loan proceeds. The amendment also modified the Consolidated Fixed Charge Coverage Ratio definition and employee equity compensation limits to $4.25M annually plus tax-withholding repurchases.
— Neutral · significance 79 · Periodic Agent
8-K Faeth Therapeutics, Inc.
Faeth announced positive Phase 2 topline results (as of October 30, 2026) for PIKTOR (serabelisib + sapanisertib) combined with paclitaxel in advanced endometrial cancer: 33% confirmed ORR (12 of 36 efficacy-evaluable patients) and 44% ORR in PIK3CA-mutant patients (7 of 16); median PFS 7.4 months with 62% 6-month PFS rate; safety profile acceptable with 12% hyperglycemia and 21% stomatitis (mostly low-grade). Company plans Phase 3 advancement pending regulatory alignment. Trial conducted with GOG Foundation across 42 treated patients with a median 2 prior therapy lines.
▲ Likely positive · significance 78 · 8-K Agent
8-K INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals priced an underwritten public offering on November 5, 2026 of 58,747,235 common shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049/warrant, with an overallotment option for 10,714,285 additional shares. Gross proceeds ~$75M before underwriting discounts (~3.1% discount to shares). Lead underwriters: Jefferies LLC and Piper Sandler Co.; H.C. Wainwright Co. as lead manager. Expected close ~November 9, 2026. Warrant exercise price $0.001/share with standard anti-dilution adjustments.
▲ Likely positive · significance 78 · 8-K Agent
8-K Netcapital Inc.
Netcapital received a Nasdaq exception on November 5, 2026, extending its deadline to file delinquent periodic reports (Form 10-K for fiscal year ended April 30, 2026, and Form 10-Q for quarter ended July 31, 2026) to February 9, 2027. The company had missed the original filing deadlines and received non-compliance notices on August 24 and September 21, 2026. Failure to file by the new deadline will trigger delisting proceedings, though the company can appeal to a Nasdaq Hearings Panel.
▼ Likely negative · significance 78 · 8-K Agent
8-K HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics agrees to sell substantially all assets of its pharmaceutical business (aprepitant/granisetron nausea products, bupivacaine/meloxicam pain products) to CorMedix Inc. for base cash consideration of $145 million, 14,583,333 shares of CorMedix common stock, plus royalty and earn-out payments (amounts redacted). Deal includes $2 million escrow and assumes specified liabilities. Requires Heron stockholder approval; CorMedix financing committed.
— Neutral · significance 78 · 8-K Agent
8-K CorMedix Inc.
CorMedix Inc. agreed to purchase Heron Therapeutics' business assets (pharmaceutical products in chemotherapy-induced nausea, post-operative nausea/vomiting, and post-operative pain) for Base Cash Consideration of $145,000,000, plus 14,583,333 shares of Buyer Common Stock, plus contingent royalty and earn-out payments. Transaction dated November 8, 2026, requires Seller stockholder approval and antitrust clearances. Buyer is financing via Loan Agreement with BioPharma Credit entities. Purchase price adjustable based on working capital (Target: $102,000,000) with $2,000,000 escrow.
▲ Likely positive · significance 78 · 8-K Agent
8-K CVR ENERGY INC
CVR Energy announced a transformational acquisition of Marathon Petroleum Corporation's St. Paul Park, Minnesota (105 mbpd) and Mandan, North Dakota (72 mbpd) refineries for approximately $4.2 billion. The deal will be financed with $1.5 billion Term Loan B, $1.0 billion other secured debt, $1.3 billion equity, $792 million cash on hand, $308 million ABL draw, and $300 million crude intermediation. Pro forma CVR will operate 384 mbpd across four PADD II refineries with ~$1.9 billion LTM Q3'26 EBITDA (155% increase), becoming the 4th largest refiner in PADD II with access to 590 branded retail locations and ~$4.5/bbl marketing margin uplift.
▲ Likely positive · significance 78 · 8-K Agent
8-K Faeth Therapeutics, Inc.
Faeth Therapeutics announced topline results from PIK-201, a Phase 2 single-arm study of PIKTOR (serabelisib + sapanisertib) plus paclitaxel in 42 patients with platinum- and immunotherapy-pretreated endometrial cancer. Confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients); median PFS 7.4 months; disease control rate 83%. Among PIK3CA-mutant patients (n unspecified), confirmed ORR was 44% and DCR 81%. Safety profile showed low PAM-class toxicity: hyperglycemia 12% (2% grade 3), stomatitis 21% (2% grade 3); only 5% discontinued for treatment-related adverse events. Company plans Phase 3 trial design disclosure in H1 2027.
▲ Likely positive · significance 78 · 8-K Agent
8-K BITMINE IMMERSION TECHNOLOGIES, INC.
As of November 8, 2026, Bitmine reported crypto holdings of 6,070,092 ETH ($13.6B at $2,234/token), 216 BTC, $475M cash/marketable securities, and $255M in moonshot investments (Beast Industries $180M, Eightco $75M), totaling $14.3B. The company has staked 5,227,037 ETH ($11.7B) through its MAVAN platform and projects $359M annualized staking rewards at full scale. Bitmine acquired 9,587 ETH in the past week and has maintained weekly ETH purchases since June 30, 2025.
▲ Likely positive · significance 78 · 8-K Agent
8-K Exascale Labs Holdings Inc.
Exascale Labs signed two identical Purchase & Sale Agreements with Taiwan-based Compal Electronics on 30 September 2026 for NVIDIA HGX B300 NVL16 servers. PO XLAB-PO-2026-0001 and PO XLAB-PO-2026-0002 each cover up to 64 units at $565,000/unit (maximum $36.16M each, total up to $72.32M). Payment structure: 20% down, 80% on shipment notice. Delivery DAP via Incoterms 2020, 4–6 weeks after downpayment, with 3-year warranty. No minimum purchase commitment; units called off by release notices through 31 March 2027. Compal retains title until full payment; security interest granted over Exascale assets. The first proforma invoice (Exhibit 10.1) shows 16 units initially ordered for $9.04M.
▲ Likely positive · significance 78 · 8-K Agent
10-Q PERMIAN BASIN ROYALTY TRUST
Permian Basin Royalty Trust (46.6M units outstanding, ticker PBT) received Q3 2026 distributable income of $3.8M ($0.08/unit), down 47% from $6.9M ($0.15/unit) in Q3 2025, despite higher oil prices ($96.85/bbl vs $62.32/bbl). A proposed business combination with Blackbeard Holdings LLC to create publicly traded PBT Land and Minerals Inc. will be voted on November 23, 2026; if approved, the Trust liquidates ~December 1, 2026. Blackbeard settlement: $9M total ($4.5M paid Sept 2025; $1.125M each in Jan/Apr/Jul/Oct 2026) resolved royalty underpayment claims.
▼ Likely negative · significance 78 · Periodic Agent
8-K Skydance Corp
On October 6, 2026, Skydance completed its acquisition of Warner Bros. Discovery using $47B equity and $57B debt, creating a combined entity with ~$44.4B in assets. The company targets $6B+ in run-rate synergies within three years (30% in year one, 70% by year two), with $1.5–$2B one-time cash costs in 2027. Management expects to reduce net leverage to 3.0x by end of 2029, reach investment-grade metrics, and achieve 3+ billion in run-rate synergies from the prior Paramount program by end of 2026. Q3 2026 (pre-acquisition) showed Paramount Skydance revenue of $7.0B (+5% YoY), adjusted EBITDA of $1.0B (14.2% margin), and $73M net earnings. The WBD acquisition is not reflected in Q3 results; consolidated reporting begins Q4 2026.
▲ Likely positive · significance 78 · 8-K Agent
8-K James River Group Holdings, Inc.
James River Group (market cap ~$230M) recorded a non-cash goodwill impairment of $181.8 million in Q3 2026, resulting in a net loss available to common shareholders of $189.4 million ($4.08 per diluted share). Excluding the impairment, adjusted net operating loss was $4.4 million ($0.10 per share), driven by $19.2 million adverse reserve development in the Excess & Surplus segment's Product Liability line (now in runoff). Tangible common equity fell 10.5% from year-end 2025 ($411.0M to $367.8M). The company also reported gross written premium decline of 22% YoY ($186.1M vs. $237.3M) and a combined ratio of 115.6% for Q3 2026 vs. 94.0% prior year.
▼ Likely negative · significance 78 · 8-K Agent
8-K Baldwin Insurance Group, Inc.
On September 14, 2026, Baldwin Insurance Group agreed to be acquired by an investor group led by Sequence AI Holdings and DFO Management in an all-cash transaction at $32.50 per share. The deal is expected to close in Q1 2027 subject to stockholder and regulatory approvals. Baldwin reported Q3 2026 revenue of $480.3M (31% YoY growth) but posted a GAAP net loss of $81.6M; adjusted EBITDA grew 47% to $106.9M with a 22.2% margin.
— Neutral · significance 78 · 8-K Agent
8-K Larimar Therapeutics, Inc.
Larimar Therapeutics completed a rolling Biologics License Application (BLA) submission to the FDA on November 9, 2026, seeking accelerated approval of nomlabofusp for Friedreich's ataxia treatment. The submission, supported by open-label study data showing sustained increases in skin frataxin (FXN) levels and directional clinical improvements, follows FDA alignment on using FXN as a novel surrogate endpoint. Larimar has $128.7M in cash as of September 30, 2026, with runway into late Q2 2027, and projects potential FDA approval by mid-2027 and U.S. launch by Q3 2027.
▲ Likely positive · significance 78 · 8-K Agent
8-K Babcock & Wilcox Enterprises, Inc.
Babcock & Wilcox reported Q3 2026 revenue of $290.8M (up 109% YoY) and net income of $93.9M, driven by large project volume including $77.8M from Base Electron and a $85.1M warrant revaluation gain. The company repurchased $38M in shares, redeemed $61.8M in 6.5% bonds due December 2026, and achieved backlog of $2.5B (up 571% YoY) and bookings of $228M (up 112%). Management issued 2027 Adjusted EBITDA guidance of $125–$140M versus 2026 guidance of $80–$105M.
▲ Likely positive · significance 78 · 8-K Agent
8-K Elmet Group Co.
Elmet reported Q3 2026 revenue of $79.6M (+55.6% YoY) and adjusted EBITDA of $17.0M (+129% YoY) with 960 bps gross margin expansion to 31.3%. The company secured a landmark $450M investment from the Department of War and a $2B long-term DLA supply agreement. Backlog surged 298% to $347.4M. Management committed $165M to expand U.S. manufacturing, $150M to Blue Moon Springer Tungsten Complex, $125M to Masan High-Tech Materials, and announced acquisition of Osram's German tungsten operations.
▲ Likely positive · significance 78 · 8-K Agent
8-K iSpecimen Inc.
iSpecimen Inc. authorized and filed a Certificate of Designations for Series D Convertible Preferred Stock on November 6, 2026. The company is issuing up to 500 shares at $800/share ($400,000 aggregate) convertible to common stock at 85% of closing price (minimum Floor Price of $0.1616). Holders receive 8% annual cumulative dividends and substantial protective rights including anti-dilution, blocking rights on capital actions, and liquidated damages provisions for delivery failures.
▼ Likely negative · significance 78 · 8-K Agent
10-Q BuzzFeed, Inc.
Allen Family Digital, LLC (controlled by Byron Allen) purchased 14,498,356 newly issued Class A shares at $0.5173/share on November 9, 2026, for approximately $7.5M, giving Allen Family Digital ~22.2% ownership. Simultaneously, BuzzFeed's CFO Matthew Omer received a 2-year employment agreement at $600K–$620K annual salary plus $400K annual RSU grants and $100K retention bonus. Allen Media and BuzzFeed also executed reciprocal media spend commitments (Allen Media commits up to $12M at 120% of BuzzFeed's spend; BuzzFeed commits up to $10M at 83.33% of Allen Media's spend) and a trademark license deal for BuzzFeed brands to rebrand LocalNow as "BuzzFeed TV" (20% of revenue above $25M base).
▲ Likely positive · significance 78 · Periodic Agent
8-K Valion Bio, Inc.
On November 6, 2026, Valion Bio closed a financing tranche with 3i, LP: 3i purchased 700 Series B Preferred Shares and warrants to buy 21,539 common shares at $0.5182/share for $700,000 aggregate. The Series B Preferred Purchase Agreement termination date was extended from December 9, 2026 to December 9, 2027. 3i also holds a $13.637M Series C position and a $16.25M convertible note.
▲ Likely positive · significance 76 · 8-K Agent
8-K Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals entered into a Loan and Security Agreement dated November 6, 2026, with Hercules Capital, Inc. as agent and lender, providing access to up to $200,000,000 in term loans across five tranches. The loan is secured by substantially all of Atea's assets, including intellectual property related to its BEM/RZR product candidate. Proceeds may be used for acquisitions, working capital, and general corporate purposes, with specific covenants tied to cash maintenance, product revenue milestones, and regulatory compliance.
▲ Likely positive · significance 76 · 8-K Agent
8-K Orchestra BioMed Holdings, Inc.
Orchestra BioMed priced a public offering of 15,000,000 common shares at $5.00 per share (gross proceeds: $75M), with underwriters Piper Sandler and TD Securities granted a 30-day option to purchase up to 2,250,000 additional shares at the same price. Net proceeds will fund AVIM Therapy and BACKBEAT trial, Virtue SAB and Virtue trial, and general corporate purposes. Offering expected to close November 9, 2026.
▼ Likely negative · significance 76 · 8-K Agent
8-K HAWAIIAN ELECTRIC INDUSTRIES INC
Hawaiian Electric Industries presented a corporate strategy emphasizing execution on four key objectives: (1) rate rebasing request of $170M revenue increase (~5.3% consolidated) with PUC proceeding ongoing, targeting 2027 implementation; (2) $400M+ wildfire mitigation and resilience spending (2025–2027), with $350M in approved WMP costs and planned securitization to limit bill impact; (3) credit rating trajectory improvement from B1/B/B− (post-wildfire 2023) to Ba2/B+/BB− as of 3Q 2026, with S&P upgrade in July 2026; (4) Maui wildfire settlement obligation of $1.99B total, with $479M first payment completed April 2026, $82M prepaid Sept/Oct 2026, and $297M second payment expected 2027. Liquidity stands at $1.32B as of 3Q 2026.
▲ Likely positive · significance 72 · 8-K Agent
8-K Canton Strategic Holdings, Inc.
On November 4, 2026, Canton Strategic Holdings (NASDAQ: CNTN) announced the first trades of its issuer-sponsored tokenized common stock on TSV LLC's permissioned venue on the Canton Network. Counterparties Five North (seller/existing shareholder), DRW Cumberland (buyer), and Flowdesk (liquidity provider) executed trades through Tradecraft's automated market maker, with Fairmint TA LLC recording shares in token form. The trades are the first under the SEC's September 17, 2026 Innovation Exemption for onshore U.S. equities and mark the first time a NASDAQ-listed company's actual stock has traded on-chain with shareholder rights intact.
▲ Likely positive · significance 72 · 8-K Agent
8-K ImmunityBio, Inc.
ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG met its primary efficacy endpoint in the randomized QUILT-2.005 registrational trial of 370 BCG-naive non-muscle invasive bladder cancer (NMIBC) patients. The chemotherapy-free combination showed statistically significant improvement over BCG alone in carcinoma in situ patients; safety profile matched BCG alone with no treatment-related deaths. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026 for this earlier-stage patient population, potentially expanding ANKTIVA's current indication (BCG-unresponsive NMIBC, approved April 2024).
▲ Likely positive · significance 72 · 8-K Agent
8-K Vivid Seats Inc.
Vivid Seats (market cap ~$123M) announced Q3 2026 Marketplace GOV of $624M, Adjusted EBITDA of $8.9M (both returning to YoY growth), and revenues of $126.9M against net loss of $17.4M. The company reached an agreement in principle with term lenders on a comprehensive recapitalization involving $60M new money term loans, conversion of significant existing debt into equity, ~$200M overall funded debt reduction, and debt maturity extension. Transaction remains subject to definitive documentation.
▲ Likely positive · significance 72 · 8-K Agent
8-K NRG ENERGY, INC.
NRG entered into a definitive agreement on November 9, 2026, to sell six natural-gas fired generation assets totaling 4.9 GW to LS Power for $4 billion in cash proceeds (subject to working capital adjustments). The transaction, expected to close Q2 2027 pending HSR, FERC, and NYSPSC approvals, retains NRG's entire PJM portfolio and CPower acquired in January 2026. Proceeds will fund $3 billion in planned debt reduction and increased share repurchases ($3 billion total across 2026–2027, including $1 billion before end of Q4 2026).
▲ Likely positive · significance 72 · 8-K Agent
8-K Target Hospitality Corp.
Since January 2026, Target Hospitality secured $1.7 billion in multi-year contract awards representing 10,000+ beds, with Workforce Hospitality Solutions (WHS) utilized beds now exceeding 6,200 as of September 30, 2026. Q3 revenue reached $129.1 million (up 30% YoY), Adjusted EBITDA grew 59% to $34.2 million with margin expansion of 480 bps to 27%, driven by WHS segment growth. The company closed a new $660 million asset-based revolving credit facility on July 24, 2026, reducing borrowing costs by up to 250 bps, and ended Q3 with $440 million total liquidity and 1.4x net leverage.
▲ Likely positive · significance 72 · 8-K Agent
8-K Constellation Energy Corp
Constellation raised adjusted operating earnings guidance to $12.50–$12.80/share (midpoint +$0.30 from prior guidance). Q3 adjusted operating earnings: $5.06/share vs. $3.04/share YoY. Key developments: (1) agreed to acquire Rhode Island State Energy Center (609 MW CCGT) from Shell for $715M; (2) signed 20-year, 690 MW PPA with Amazon (~$3B capex commitment at Calvert Cliffs); (3) signed 20-year PPA with Google for 890 MW uprates across 11 units (~$4.3B investment); (4) received conditional DOE loan commitment for up to $5.0B at T+37.5bps to fund nuclear uprates; (5) signed first Peak+ agreement for 270 MW over 20 years. Total announced MW contracts YTD: ~5,500 MW premium long-term agreements.
▲ Likely positive · significance 72 · 8-K Agent
8-K OCULAR THERAPEUTIX, INC
Ocular Therapeutix reported Q3 2026 results with cash of $530.6M (sufficient runway into 2028) and announced AXPAXLI NDA submission on track for Q4 2026 under 505(b)(2) pathway for wet AMD, supported by SOL-1 Week 52 efficacy data and interim SOL-R Week 52 safety data from >300 patients. SOL-R primary endpoint moved to Week 40 (from Week 56) to preserve statistical integrity ahead of interim safety analysis; preliminary SOL-R screening shows ~20% of otherwise eligible subjects excluded due to early persistent retinal fluid, aligned with company expectations. Company appointed commercial veteran Riad Sherif to Board; Q3 net loss was $94.8M on revenue of $12.9M.
▲ Likely positive · significance 72 · 8-K Agent
8-K Immunovant, Inc.
Immunovant's lead candidate IMVT-1402 600 mg achieved the primary endpoint of ACR20 response in Period 2 of its potentially registrational difficult-to-treat rheumatoid arthritis (D2T RA) trial: 92.5% vs. 75.6% placebo (p=0.0139), with 117 participants randomized (40 on 600mg, 36 on 300mg, 41 placebo). The company halted further development in Sjögren's disease beyond the ongoing Phase 2 trial. FDA discussions are planned for late 2026 on the RA registrational path. Cash position: $722.3M as of September 30, 2026; 206,785,540 shares outstanding.
▲ Likely positive · significance 72 · 8-K Agent
8-K Tango Therapeutics, Inc.
Tango Therapeutics reported 82% ORR and 88% 9-month PFS in Phase 1/2 study of vopimetostat plus daraxonrasib (Revolution Medicines' RAS inhibitor) in 2L/3L MTAP-deleted pancreatic cancer, with generally well-tolerated safety profile at dose vopimetostat 200 mg/daraxonrasib 100 mg daily. Company plans to initiate a registrational Phase 3 study in front-line MTAP-deleted pancreatic cancer in 1H 2027 and will discuss accelerated approval in second-line setting with regulators. Cash position stands at $977.5M as of Sept 30, 2026; R&D expenses increased to $48.9M (Q3 2026) vs $30.8M (Q3 2025) and $119.7M (9M 2026) vs $100.1M (9M 2025); net loss of $68.4M (Q3 2026) vs net income $15.9M (Q3 2025).
▲ Likely positive · significance 72 · 8-K Agent
8-K Cullinan Therapeutics, Inc.
Cullinan's BCMAxCD3 T cell engager velinotamig (licensed from Genrix Bio) treated 12 patients across three dose cohorts as of September 8, 2026. Among 9 evaluable patients with ≥4 weeks follow-up, 8 of 9 achieved ≥4-point SLEDAI-2K reduction; 4 of 7 with baseline proteinuria >500 mg/24h achieved complete renal response (<500 mg/24h) within 24 weeks. Safety profile was favorable: zero dose-limiting toxicities, zero ICANS, no Grade 3+ CRS (only Grade 1–2 in 2 patients, resolved with standard management).
▲ Likely positive · significance 72 · 8-K Agent
8-K Viridian Therapeutics, Inc.\DE
Viridian announced positive Phase 1 results for VRDN-008, a subcutaneous FcRn inhibitor licensed from Paragon Therapeutics, demonstrating 74% peak IgG reduction sustained through 8 weeks with a 15–18 day half-life (6x longer than first-gen Fc fragments), supporting every-8-week dosing via the Enable enFuse injector. The company plans to initiate a registrational trial in myasthenia gravis in mid-2027 (pending regulatory feedback) with Q4W and Q8W dosing arms, and to expand development into multiple autoimmune diseases; no serious adverse events or dose-limiting toxicities were reported.
▲ Likely positive · significance 72 · 8-K Agent
8-K SIRIUS XM HOLDINGS INC.
Sirius XM appointed Anjali Sud as CEO effective January 1, 2027, replacing Jennifer Witz who is transitioning to advisory role through end of 2027. Sud's compensation includes: $2.6M annual base salary; $4.5M signing-on RSUs (1/3 vest on grant date, 1/3 at 1-year, 1/3 at 2-year anniversaries); $4.5M target performance RSUs (3-year performance period 2027–2029); $9M minimum annual equity grants for 2028–2029; 200% target annual bonus; and severance of 2–3x base plus bonus if terminated without cause. Witz receives $175K/month consulting fee through end of 2027 plus vested options and pro-rata 2026 bonus.
— Neutral · significance 72 · 8-K Agent
8-K Quanome Technologies, Inc.
Quanome Technologies (QNME, market cap ~$20.3M) entered a stock purchase agreement dated November 4, 2026 with QAI Labs Ltd to acquire 31,579 newly issued shares (representing ~5% of QAI Labs post-issuance). Quanome will issue 6,541,236 common shares (~19% pre-issuance dilution, ~15.97% post-issuance) valued at $5M aggregate consideration, implying a $100M QAI Labs valuation. Closing is subject to customary conditions; QAI Labs remains independent, pre-commercial developer of NOVA-3 AI platform for antibody discovery.
— Neutral · significance 72 · 8-K Agent
8-K DELCATH SYSTEMS, INC.
Delcath Systems reported Q3 2026 total revenue of $35.1M (up 71% YoY from $20.6M), with HEPZATO KIT revenue of $32.7M (up 69% YoY from $19.3M) and CHEMOSAT of $2.4M (up 85% YoY from $1.3M). Net income reached $7.0M vs. $0.8M YoY; adjusted EBITDA grew 117% to $11.5M. Management raised full-year 2026 revenue guidance to $115–117M (up from prior range), projecting ≥41% HEPZATO volume growth over 2025, with gross margins of 87–89% and positive adjusted EBITDA. Cash position strengthened to $104.3M with zero debt; company expanded to 33 active treatment centers and advanced Phase 2 DELUMA trial for breast cancer indication.
▲ Likely positive · significance 72 · 8-K Agent
8-K SPRUCE BIOSCIENCES, INC.
Spruce Biosciences amended its Avenue Capital loan on November 6, 2026, increasing Tranche 2 availability to $15M (drawable Jan–Mar 2027) and extending the interest-only period through March 31, 2027 (potentially to October 2028). Simultaneously, Spruce separated its CRHX-101 program into a wholly-owned subsidiary, Adrenyx Biosciences, which raised $5M in secured convertible notes from an institutional investor with up to $10M available and $50M expected in a future private placement; Spruce plans to distribute all Adrenyx shares pro-rata to shareholders in H1 2027. TA-ERT BLA submission remains on track for December 2026; Q3 2026 cash was $87.7M (vs. $48.9M at year-end 2025); net loss was $24M for Q3 2026 ($52.5M for nine months).
▲ Likely positive · significance 72 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.